文献速递乳腺癌

阿替利珠单抗联合新辅助抗人表皮生长因子受体2治疗及化疗用于人表皮生长因子受体2阳性早期乳腺癌:随机III期IMpassion050试验主要结果

Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
PubMed 文献 · J Clin Oncol · 2022-06-28

IMpassion050是一项随机III期试验,评估在高危HER2阳性早期乳腺癌患者中,于标准治疗(帕妥珠单抗-曲妥珠单抗联合化疗)基础上加用阿替利珠单抗能否提高病理完全缓解率。结果显示,在ITT人群和PD-L1阳性人群中,阿替利珠单抗组与安慰剂组的pCR率均无显著差异。阿替利珠单抗组3-4级和严重不良事件更常见,结论认为PH联合化疗仍是标准治疗。

要点

  • ITT人群pCR率:安慰剂组62.7% vs 阿替利珠单抗组62.4%,差异无统计学显著。
  • PD-L1阳性人群pCR率:安慰剂组72.5% vs 阿替利珠单抗组64.2%,差异无统计学显著。
  • 阿替利珠单抗组3-4级和严重不良事件更常见,发生5例5级不良事件。

核心结论

  • 在高危HER2阳性早期乳腺癌中,新辅助阿替利珠单抗联合剂量密集多柔比星/环磷酰胺-紫杉醇及帕妥珠单抗-曲妥珠单抗,相比安慰剂并未提高ITT或PD-L1阳性人群的pCR率。
  • 帕妥珠单抗-曲妥珠单抗联合化疗仍是标准治疗;更长的随访可能有助于了解阿替利珠单抗的长期影响。

研究设计与样本

  • 随机III期IMpassion050试验,纳入原发肿瘤>2 cm且组织学证实淋巴结阳性(T2-4,N1-3,M0)的HER2阳性早期乳腺癌患者。
  • 患者按1:1随机分配接受阿替利珠单抗或安慰剂,联合剂量密集多柔比星/环磷酰胺,序贯紫杉醇及帕妥珠单抗-曲妥珠单抗;术后继续阿替利珠单抗/安慰剂和帕妥珠单抗-曲妥珠单抗(总疗程1年HER2靶向治疗),有残留病灶者可换用ado-曲妥珠单抗 emtansine联合阿替利珠单抗/安慰剂。
  • 共同主要疗效终点为意向治疗(ITT)人群和程序性细胞死亡配体1(PD-L1)阳性人群的病理完全缓解(pCR;ypT0/is ypN0)率。

主要发现

  • 截至临床 cutoff(2021年2月5日),ITT人群中安慰剂组pCR率为62.7%(n=143/228),阿替利珠单抗组为62.4%(n=141/226),差异为-0.33%(95%CI,-9.2至8.6;P=0.9551)。
  • PD-L1阳性肿瘤患者中,安慰剂组pCR率为72.5%(n=79/109),阿替利珠单抗组为64.2%(n=70/109),差异为-8.26%(95%CI,-20.6至4.0;P=0.1846)。
  • 阿替利珠单抗组3-4级和严重不良事件比安慰剂组更频繁。
  • 共发生5例5级不良事件(4例新辅助阶段,1例辅助阶段;其中2例归因于研究治疗),均发生在阿替利珠单抗组。
  • 总体安全性特征与阿替利珠单抗在其他联合研究中的表现一致。

关键数值与推荐

  • ITT人群pCR率:安慰剂组62.7%(143/228) vs 阿替利珠单抗组62.4%(141/226),差异-0.33%(95%CI,-9.2至8.6;P=0.9551)。
  • PD-L1阳性人群pCR率:安慰剂组72.5%(79/109) vs 阿替利珠单抗组64.2%(70/109),差异-8.26%(95%CI,-20.6至4.0;P=0.1846)。

临床怎么用

  • 帕妥珠单抗-曲妥珠单抗联合化疗仍是高危HER2阳性早期乳腺癌的标准治疗。
  • 原文未据此给出阿替利珠单抗联合方案的推荐。

局限性

  • 更长的随访可能有助于了解阿替利珠单抗的长期影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Combining standard of care (pertuzumab-trastuzumab [PH], chemotherapy) with cancer immunotherapy may potentiate antitumor immunity, cytotoxic activity, and patient outcomes in high-risk, human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We report the phase III IMpassion050 primary analysis of neoadjuvant atezolizumab, PH, and chemotherapy in these patients. METHODS: Patients with a primary tumor of > 2 cm and histologically confirmed, positive lymph node status (T2-4, N1-3, M0) were randomly assigned 1:1 to atezolizumab/placebo with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel, and PH. After surgery, patients were to continue atezolizumab/placebo and PH (total: 1 year of HER2-targeted therapy); those with residual disease could switch to ado-trastuzumab emtansine with atezolizumab/placebo. Coprimary efficacy end points were pathologic complete response (pCR; ypT0/is ypN0) rates in intention-to-treat (ITT) and programmed cell death-ligand 1 (PD-L1)-positive populations. RESULTS: At clinical cutoff (February 5, 2021), pCR rates in the placebo and atezolizumab groups in the ITT populations were 62.7% (n = 143/228) and 62.4% (n = 141/226), respectively (difference -0.33%; 95% CI, -9.2 to 8.6; P = .9551). The pCR rates in the placebo and atezolizumab groups in patients with PD-L1-positive tumors were 72.5% (n = 79/109) and 64.2% (n = 70/109), respectively (difference -8.26%; 95% CI, -20.6 to 4.0; P = .1846). Grade 3-4 and serious adverse events were more frequent in the atezolizumab versus placebo group. Five grade 5 adverse events occurred (four neoadjuvant, one adjuvant; two assigned to study treatment), all with atezolizumab. Overall, the safety profile was consistent with that of atezolizumab in other combination studies. CONCLUSION: Atezolizumab with neoadjuvant dose-dense doxorubicin/cyclophosphamide-paclitaxel and PH for high-risk, HER2-positive early breast cancer did not increase pCR rates versus placebo in the ITT or PD-L1-positive populations. PH and chemotherapy remains standard of care; longer follow-up may help to inform the long-term impact of atezolizumab.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Huober J, Barrios CH, Niikura N, et al. Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. J Clin Oncol. 2022. PMID: 35763704. doi:10.1200/JCO.21.02772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。